《瑞银窝轮》药股发力看好留意石药购27355
小米(1810)已公布业绩，上季经调整盈利按年升72%，按季升75%，好过市场预期，不过市场担心5G年代小米盈利或会受压，股份业绩过後出现沽压，周三最低见8.81港元，下跌6.5%，经过周三的下跌，小米已蒸发8月以来的升幅，股价暂时在10天线争持。根据瑞银於星期三的即市资金流纪录，资金流入小米，反映投资者或看好小米集团短线的走势。如投资者看好小米，可留意小米集团认购20067，行使价9.51港元，19年12月到期，有效杠杆约7.5倍。相反，如投资者看淡小米，可留意小米集团认沽21408，行使价8.38港元，20年3月到期，有效杠杆约3.1倍。
周三表现比较强的股份则可留意药股，石药集团(1093)股价最高见15.58港元，上升8.1%，同业中国生物制药(1177)最高见10.82港元，再创52周高位。药股周三的急升主要受惠医保局将128种药品纳入拟谈判准入范围。事实上药股是较强的板块，中生制药近2个月更反覆上升，经过周三的急升，石药和中生制药现时的9天RSI相对强弱指数已升穿70，为市场人士普遍认为超买的水平，不过由於受惠政策，周三仍有资金追入药股的认购证。不过由於近日石药集团升势非常急，之前较热门的认购证或已变得非常贴价或价内，令有效杠杆降低，如投资者看好石药，可留意石药价外认购27355，行使价16.38港元，19年12月到期，有效杠杆约5.6倍。
更多窝轮牛熊资讯：瑞银证网站: www.ubs.com/hkwarrants卓素华董事
瑞银亚洲股票衍生产品销售部
本产品并无抵押品。 如发行人无力偿债或违约,投资者可能无法收回部份或全部应收款项。笔者为UBS AG的代表(作为证监会持牌人)，并未持有相关上市公司的任何财务权益。本资料由瑞银刊发，其并不构成买卖建议、邀请、要约或游说。结构性产品价格可急升或急跌，投资者可能会蒙受全盘损失。过往表现并不反映将来表现。牛熊证备强制赎回机制而可能被提早终止，届时 (i) N类牛熊证投资者将不获发任何金额;而(ii) R类牛熊证之剩余价值可能为零。投资前应了解有关风险，并谘询专业顾问及查阅有关上市文件。UBS Securities Hong Kong Limited为结构性产品之流通量提供者，亦可能是唯一报价者或市场参与者。c UBS 2019。版权所有。~重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
